| Literature DB >> 28847964 |
Kiyotoshi Satoh1, Shinichi Yachida2, Masahiro Sugimoto1, Minoru Oshima3, Toshitaka Nakagawa4, Shintaro Akamoto3, Sho Tabata1, Kaori Saitoh1, Keiko Kato1, Saya Sato1, Kaori Igarashi1, Yumi Aizawa1, Rie Kajino-Sakamoto5, Yasushi Kojima5, Teruaki Fujishita5, Ayame Enomoto1, Akiyoshi Hirayama1, Takamasa Ishikawa1, Makoto Mark Taketo6, Yoshio Kushida3, Reiji Haba3, Keiichi Okano3, Masaru Tomita1, Yasuyuki Suzuki3, Shinji Fukuda1, Masahiro Aoki5, Tomoyoshi Soga7.
Abstract
Cancer cells alter their metabolism for the production of precursors of macromolecules. However, the control mechanisms underlying this reprogramming are poorly understood. Here we show that metabolic reprogramming of colorectal cancer is caused chiefly by aberrant MYC expression. Multiomics-based analyses of paired normal and tumor tissues from 275 patients with colorectal cancer revealed that metabolic alterations occur at the adenoma stage of carcinogenesis, in a manner not associated with specific gene mutations involved in colorectal carcinogenesis. MYC expression induced at least 215 metabolic reactions by changing the expression levels of 121 metabolic genes and 39 transporter genes. Further, MYC negatively regulated the expression of genes involved in mitochondrial biogenesis and maintenance but positively regulated genes involved in DNA and histone methylation. Knockdown of MYC in colorectal cancer cells reset the altered metabolism and suppressed cell growth. Moreover, inhibition of MYC target pyrimidine synthesis genes such as CAD, UMPS, and CTPS blocked cell growth, and thus are potential targets for colorectal cancer therapy.Entities:
Keywords: MYC; colorectal cancer; metabolism; metabolomics; omics
Mesh:
Substances:
Year: 2017 PMID: 28847964 PMCID: PMC5604037 DOI: 10.1073/pnas.1710366114
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205